Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

2014 ASCO Annual Meeting

30 May - 3 Jun 2014

Published: 2 Jun 2014

Rating:

Save

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

Prof Topp talks to ecancertv at ASCO 2014 about the results of a multicentre phase 2 study of the BiTE antibody blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia. The use of blinatumomab is an antibody treatment which enables chemotherapy to be bypassed in some patients.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA

11 Mar 2025

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

28 Oct 2024

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

28 Oct 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

15 Sep 2024

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

26 Jun 2024

Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma

Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA

$Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma ( Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA )$